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ABSTRACT
Oral drug delivery is an attractive noninvasive alternative to injectables. However, oral delivery of bio-
pharmaceuticals is highly challenging due to low stability during transit in the gastrointestinal tract
(GIT), resulting in low systemic bioavailability. Thus, novel formulation strategies are essential to over-
come this challenge. An interesting approach is increasing retention in the GIT by utilizing mucoadhe-
sive biomaterials as excipients. Here, we explored the potential of the GRAS excipient sucrose acetate
isobutyrate (SAIB) to obtain mucoadhesion in vivo. Mucoadhesive properties of a 90% SAIB/10% EtOH
(w/w) drug delivery system (DDS) were assessed using a biosimilar mucus model and evaluation of
rheological behavior after immersion in biosimilar intestinal fluid. To ease readability of this manu-
script, we will refer to this as SAIB DDS. The effect of SAIB DDS on cell viability and epithelial mem-
brane integrity was tested in vitro prior to in vivo studies that were conducted using SPECT/CT
imaging in rats. When combining SAIB DDS with biosimilar mucus, increased viscosity was observed
due to secondary interactions between biosimilar mucus and sucrose ester predicting considerable
mucoadhesion. Mucoadhesion was confirmed in vivo, as radiolabeled insulin entrapped in SAIB DDS,
remained in the small intestine for up to 22h after administration. Moreover, the integrity of the sys-
tem was investigated using the dynamic gastric model under conditions simulating the chemical com-
position of stomach fluid and physical shear stress in the antrum under fasted conditions. In
conclusion, SAIB is an interesting and safe biomaterial to promote high mucoadhesion in the GIT after
oral administration.
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Introduction
Sucrose acetate isobutyrate (SAIB) is commonly used as an
emulsion stabilizer in soft drinks and has been shown to
remain in the gastrointestinal tract (GIT) for up to 24 h
(Phillips et al., 1976), due to both limited absorption and
degradation. SAIB is a sucrose derivative, obtained by full
esterification of sucrose with acetate and isobutyrate groups,
and it is generally regarded as safe (GRAS) by the U.S. Food
and Drug Administration (FDA) (U.S. Food and Drug
Administration, 2018). Interestingly, the potential of using
SAIB has been studied in injectable drug delivery systems
(DDSs) for small molecules (Lee et al., 2006; Lu et al., 2008;
Wang et al., 2018). In those studies, SAIB was used to form a
water insoluble, yet biodegradable, matrix when mixed with
10% ethanol resulting in a matrix from where the investi-
gated drugs were released in a sustained manner. Also, a
marketed SAIB-based product exists for long-acting injectable
risperidone and bupivacaine formulations (Durect
Corporation, 2016).
A noninvasive alternative to drug delivery by injection is
oral administration (Renukuntla et al., 2013; Lam & Gambari,
2014). Successful oral delivery may, however, be greatly chal-
lenged by the low stability of drugs in the gastrointestinal
(GI) tract, especially for peptides, proteins, and other biophar-
maceuticals, which represents a growing part of the pharma-
ceutical portfolio (Hamman et al., 2005). Low stability is
caused by the harsh luminal conditions including the pres-
ence of proteolytic enzymes and the significant variations in
pH (Hwang & Byun, 2014). Moreover, the large molecular
size of biopharmaceuticals limits their penetration into and
through not only the mucus layer lining the epithelial surface
but also the epithelial membrane. Much work has been done
to overcome these obstacles, utilizing various strategies to
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increase the overall transmucosal absorption by employing
absorption enhancers, enzyme inhibitors, and mucoadhesive
polymers (Khafagy et al., 2007; Li et al., 2012; Hwang & Byun,
2014) in order to deliver intact pharmacologically functional
molecules. Moreover, the focus has been on protecting the
biopharmaceutical from being rapidly degraded when traf-
ficking through the harsh GI environment by using advanced
DDSs (Park et al., 2011; Garcıa-Dıaz et al., 2015).
A growing interest among researchers exists regarding
delivery via the GI mucosa (Boegh et al., 2013). One strategy
is to increase the contact time between the DDS and target
site for absorption (Ivarsson & Wahlgren, 2012; Reineke et al.,
2013), hence improve the flux of the drug across the muco-
sal membrane and thus enhance its systemic bioavailability.
Thus, SAIB is a highly relevant biomaterial to consider for
oral administration of drugs due to (1) a proven prolonged
residence time in the GIT (Reynolds & Chappel, 1998), (2) its
capability to form a biodegradable matrix from where drugs
can be released in a controlled manner (Lu et al., 2008; Jølck
et al., 2014), and (3) its status as a GRAS excipient (Food
Additive Status List, 2002). However, to the best of our
knowledge, the mucoadhesive behavior of SAIB, hence
potential as a non-injectable biomaterial, still remains to
be studied.
Thus, the present work explored the potential of SAIB as
a biomaterial to obtain mucoadhesion in vivo. First, rheo-
logical profiling of SAIB DDS was done at various tempera-
tures, after incubation in biorelevant media and upon mixing
with biosimilar mucus to assess the mucoadhesive behavior.
Second, we studied the effect of physical shear stress on the
SAIB DDS in the antrum using an advanced dynamic gastric
model. Insulin was used as a model cargo to evaluate the
capability of the SAIB DDS to retain a poorly stable drug
when subjected to the harsh GI environment. As a control,
release studies of insulin were done in both 10mM MES buf-
fer and simulated small intestinal fluid (SSIF) (both pH 6.5),
and the release profile was related to both rheological prop-
erties of SAIB, hence microstructure during the experiment.
Third, the mucoadhesive behavior of orally administered
SAIB DDS loaded with 123I-labeled insulin was studied in
F344/NCrHsd rats using SPECT/CT imaging. Prior to the in
vivo studies, the effect on epithelial integrity and cell viability
was evaluated in vitro.
Materials and methods
Chemicals and reagents
Human insulin was kindly provided by Sanofi-Aventis
Deutschland (Frankfurt, Germany). 4-Morpholineethanesul-
fonic acid (MES) and 4-(2-hydroxyethyl)piperazine-1-ethane-
sulfonic acid (HEPES) were purchased from AppliChem
(Darmstadt, Germany), polyacrylic acid (PAA) (CarbopolVR
974P NF) from Lubrizol (Brussels, Belgium), SAIB, trypan blue,
Hanks’ balanced salt solution (HBSS), mucin from porcine
stomach type II, bovine serum albumin (BSA) (98%), choles-
terol (>99%), polysorbate 80, sodium taurocholate, sodium
dodecyl sulfate, potassium dihydrophosphate, sodium thio-
sulfate, sodium chloride, potassium chloride, calcium
chloride, monosodium phosphate, chloramine T, Dulbecco’s
modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), penicillin/streptomycin, L-glutamine, and non-essential
amino acids from Sigma-Aldrich (St. Louis, MO), soybean
phosphatidylcholine and phosphatidylcholine (PC, purity
98%) from Lipoid (Ludwigshafen am Rhein, Germany), 3H-
mannitol (1mCi) and Ultima Gold scintillation fluid from
PerkinElmer (Cleveland, OH), Na-123I from MAP MEDICAL
(Tikkakoski, Finland), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (CellTiter
96VR AQueous MTS Reagent Powder), and phenazine methosul-
fate (PMS) from Promega (Fitchburg, WI). All other chemicals
used were of analytical grade and obtained from commercial
sources. For RP-HPLC, solvents were HPLC-grade. Ultrapure
water was used throughout the study and prepared using
a Barnstead NanoPure system (Thermo Scientific,
Waltham, MA).
Preparation of test material and buffers
Based on previous studies (Okumu et al., 2002; Pechenov
et al., 2004; Lu et al., 2007, 2008), SAIB DDS was prepared by
adding 10% (w/w) ethanol (96%) to SAIB, allowing it to dis-
solve at 37 C overnight. Subsequently, the SAIB DDS was
stored at room temperature (RT) up to 14 days in a sealed
blue cap bottle. For loading insulin into the SAIB DDS, insulin
dry powder was added to the SAIB DDS under gentle stirring
to a final concentration of 0.5% (w/w) after which the SAIB
DDS was sonicated for 10min to suspend the protein
homogeneously.
Biosimilar mucus was prepared the day prior to experi-
ment according to the method previously described by our
group (Boegh et al., 2014, 2015). In brief, PAA (0.9% w/v)
was dissolved in 10mM HEPES buffer, and 1.3mM calcium
chloride and 1.0mM magnesium sulfate added under mag-
netic stirring. Subsequently, mucin was added (5% w/v) and
pH adjusted toward neutral pH using sodium hydroxide
(NaOH). A mixture of polysorbate 80 (0.16% w/v), cholesterol
(0.36% w/v), and PC (0.18% w/v) was added together with
BSA (3.1% w/v) and pH adjusted to 7.4 with NaOH. Prior to
use, the biosimilar mucus was stored overnight at 4 C.
Labeling of insulin with 123I for SPECT/CT imaging was
done by dissolving insulin (1mg) in 800 mL 10mM HCl. Then,
200 mL of 0.5 M monopotassium phosphate (KH2PO4) buffer
(pH 5.0) was added to the solution. To 500 mL of the result-
ing solution, 300 mL of 0.2 M KH2PO4 buffer (pH 5.0) and
120 mL of Na-123I (109.2 MBq) were added. The reaction was
started by addition of 10 mL of chloramine T solution (1mg/
mL). The reaction mixture was mixed well and left at RT.
After 3min, the reaction was stopped by addition of 10 mL
of sodium thiosulfate (2.5mg/mL) solution in ultrapure water.
After 5min, the reaction mixture was applied on an RP cart-
ridge (Sep-Pac C18, Waters, Milford, MA), the cartridge was
washed with 3mL of deionized water to remove unreacted
low molecular weight compounds and salt. The product was
washed from the cartridge with 2mL of 60% (v/v) acetonitrile
containing 0.01% (v/v) HCl to give a mixture of insulin and
radioactively labeled insulin (70 MBq). Then, solvents were
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removed in vacuum, and the residue was dissolved in 0.7mL
ethanol containing 0.1% (v/v) HCl, giving a radioactive yield
of 64%. The radioactive purity was determined by HPLC (HP
1050, Agilent Technologies Inc., Palo Alto, CA), equipped
with X bridgeTM C18 (5 mm, 4.6 150mm, Waters, Milford,
MA). The linear gradient for mobile phase B was set from 0
to 60% over 30min with a flow rate of 1mL/min. The mobile
phase A consisted of 0.1% (v/v) TFA/99.1% (v/v) ultrapure
water and B consisted of 0.1% TFA (v/v)/80% acetonitrile (v/
v)/19.9% (v/v) ultrapure water.
Four buffers were prepared: 10mM MES and SSIF, both
pH 6.5. SSIF consisted of sodium taurocholate (3mM),
sodium phosphatidylcholine (SPC) (0.2mM), maleic acid
(19mM), and sodium chloride (68mM) in ultrapure water, as
previously described (Garcıa-Dıaz et al., 2015). The buffers
were stirred overnight, and pH adjusted to 6.5. For in vitro
experiments, a 10mM HEPES HBSS buffer pH 7.4 was pre-
pared by dissolving HEPES in HBSS (hHBSS) and a 10mM
MES HBSS buffer pH 6.5 (mHBSS). The buffers for in vitro
experiments were further added 0.5% (w/v) BSA to offset
nonspecific binding.
Biophysical characterization of the SAIB DDS
Small deformation rheology
An ARES-G2 Rheometer (TA Instruments, New Castle, DE)
equipped with a Peltier plate and truncated cone (1, 20mm
from TA Instruments, New Castle, DE) was used for all rheo-
logical measurements. To prevent evaporation from the sam-
ple, a solvent trap cover was used. All tests were run within
the linear viscoelastic region.
The effect of temperature on the elastic modulus (G0) of
the SAIB DDS was evaluated using a temperature sweep
from 5 to 50 C (1 C/min) using an angular frequency of
1 rad/s and an oscillatory stress of 1 Pa. To evaluate the effect
of storage conditions, time and immersion in test media
(10mM MES and SSIF, pH 6.5) on the SAIB DDS, a frequency
sweep was conducted with an increasing angular frequency
from 0 to 10 rad/s and an oscillatory stress of 1 Pa. Stress
sweep tests were measured with an increasing oscillatory
stress from 0 to 500 Pa and an angular frequency set to
1 rad/s.
Mucoadhesion of the SAIB DDS to biosimilar mucus was
evaluated using a slightly modified version of a previously
described method (Hassan & Gallo, 1990; Ivarsson &
Wahlgren, 2012). Due to limitations in sample amount, the
cone-plate geometry was used. The samples were analyzed
using continuous ramp flow with increasing shear rates from
0 to 25 s–1 sampling five points per decade. The instrument
was set to automatically await temperature equilibrium at
37 C before starting the measurement. The SAIB DDS and
biosimilar mucus were prepared as described in the section
preparation of test material and buffers. In addition, mixed
samples in ratios of 2:1, 1:1, and 1:2 (v/v), biosimilar
mucus:SAIB DDS were prepared on the day of analysis using
magnetic stirring for 15min.
Loss on drying
Loss on drying was determined according to monographs for
loss on drying and sucrose, as described in the British
Pharmacopoeia (British Pharmacopoeia, 2015). Briefly, the
weight of the samples was measured before and after plac-
ing the samples in an oven at 105 C for at least 24 h.
Subsequently, the weight was measured again and the per-
centage loss of weight calculated.
Microstructure
The microstructure of the SAIB DDS was investigated both
after 8 h of exposure to MES or SSIF buffer as well as before
and after subjecting the SAIB DDS to the dynamic gastric
model. The images were captured using a bright-field micro-
scope using 100 magnification (Nikon Eclipse Ti-S, Tokyo,
Japan), equipped with a Lumenera camera (Lumenera,
Ottawa, Canada).
Effect of gastric processing on integrity and
insulin release
The dynamic gastric model experiments were performed
according to previous studies (Vardakou et al., 2011;
Wickham et al., 2012), using a constant volume of 50mL,
simulating fasted state in vivo conditions. The addition of
simulated gastric juice was performed at a constant rate of
1mL/min, and the dynamic gastric model was programed to
eject 10mL samples every 10min. Fluid compositions were
as follows: gastric acid solution: 58mM NaCl, 30mM KCl,
0.5mM CaCl2, 0.86mM NaH2PO4, and 20mM HCl, pH 2. Since
fasted state conditions including fasted state secretions of
gastric juices were simulated, a flow rate of 1mL of gastric
acid solution was used. The experiments were performed by
adding 2 g insulin-loaded SAIB DDS to the fundus/corpus
compartment, followed by 40min processing. Four samples
were collected and analyzed for insulin content over this
period, along with the 50mL residual collected when termi-
nating the experiment. Insulin release was quantified using
RP-HPLC (Ultimate 3000, Dionex, Thermo Fisher Scientific,
Waltham, MA) equipped with an Aeris Widepore XB-C18 col-
umn (100 2.1mm, 3.6 mm, Phenomenex, Torrance, CA) and
UV detection at 214 and 275 nm. The mobile phase A con-
sisted of ultrapure water with 0.1% (v/v) trifluoroacetic acid
(TFA), and the mobile phase B consisted of acetonitrile/0.1%
(v/v) TFA. Insulin was eluted using a linear gradient of mobile
phase B from 20 to 60% over 3.5min at a flow rate of
0.8mL/min and using a column temperature of 40 C. The
injection volume was 10 mL, and standard curves of insulin
dissolved in the relevant medium were linear in the range of
0.5–500 mg/mL.
Release behavior
The SAIB DDS was evaluated by adding 100mg of the insu-
lin-loaded SAIB DDS to 3mL 37 C MES or SSIF. The loaded
SAIB DDS samples were maintained at 37 C under constant
linear shaking using a water bath (GLS400, Grant
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Instruments, Cambridge, UK). Sample volumes of 100 mL
were collected after 0, 15, 30, 45, 60, 120, 180, 240, 300, 360,
and 1440min at 37 C and replenishment with buffer was
done. To prevent degradation of insulin after sampling, 5 mL
2% (v/v) formic acid was added to collected samples (Boegh
et al., 2015). Finally, insulin release was quantified as
described in the method for effect of gastric processing on
integrity and insulin release.
In vitro evaluation in the Caco-2 cell culture model
3H-mannitol was used as a paracellular epithelial permeabil-
ity marker to assess the influence of SAIB DDS on the epithe-
lial integrity using the human colon adenocarcinoma cell
line; Caco-2 cells (American Type Culture Collection,
Rockville, MD). The cells were cultured in DMEM medium
supplemented with 10% (v/v) FBS, penicillin (100U/mL),
streptomycin (100lg/mL), 1% (v/v) L-glutamine, and 1% (v/v)
non-essential amino acids (DMEMþ). Cells in T75 culturing
flasks were kept at 37 C in a 5% CO2 humidified atmosphere
and passaged weekly. Passage numbers used were 25–31.
The cells were seeded 20 days prior to the experiment by
adding 0.5mL cell suspension onto polycarbonate filter
inserts (1.12 cm2 growth area, pore size of 0.4 lm) in a 12-
well plate (Corning Costar, Tewksbury, MA) in a concentra-
tion of 8.9 10–4 cells/cm2. Culturing was done with 1mL
DMEMþ in the well and 0.5mL DMEMþ in the insert and
replacing this medium with fresh medium every other day.
To evaluate the effect of SAIB DDS on epithelial integrity
and cell viability, the 3H-mannitol loaded SAIB DDS was
applied to the cell monolayers in amounts of 50 mL or
150 mL at time 0, and supplemented with mHBSS buffer to a
total volume of 400 mL. To prepare the loaded SAIB DDS, 3H-
mannitol solution (1 lCi/mL in ethanol) was prepared and
mixed with the SAIB DDS to allow for using a final concen-
tration of 2.5 mCi/insert. The dosed volumes of the SAIB DDS
were added to a scintillation vial in order to determine the
exact 3H-mannitol donor starting concentration. Samples of
100 mL were withdrawn from the basolateral side of the
monolayer every 15min during the first hour and after that
every 30min for up to 4 h with replenishment of buffer after
each sample withdrawal. Throughout the experiment, the
cells were kept for 4 h at 37 C, while placed on a benchtop
orbital shaker (MaxQ2000, Thermo Fischer Scientific,
Waltham, MA) set to 100 rpm. TEER was measured before
and after the experiment after 15min equilibration in hHBSS
at RT, using a resistance chamber (Endohm-12, World
Precision Instruments, Sarasota, FL) connected to a voltmeter
(EVOM, World Precision Instruments, Sarasota, FL). As a con-
trol, 50 mL SAIB DDS was added to the cells and 370 mL
mHBSS buffer containing 3H-mannitol was added. Samples of
100 mL were immediately collected from the apical side, and
mixed by vortex with 2mL scintillation fluid (Ultima Gold,
PerkinElmer, Waltham, MA) in sealed vials prior to analysis
using a Tri-Carb 2100 TR liquid scintillation analyzer
(Canberra Packard, Dreieich, Germany).
Subsequent to the membrane integrity study, the effect
on cell viability was evaluated. The cell monolayers were
washed twice with hHBSS buffer pre-warmed to 37 C and
320 mL MTS/PMS solution (0.24mg/mL MTS, 4.8lg/mL PMS
in hHBSS) was added on the apical side of each monolayer.
The cell monolayers were then kept for 1.5 h at 37 C using
the before mentioned benchtop orbital shaker set to
100 rpm. Subsequently, aliquots of 100 mL from each insert
were transferred to a 96-well plate (Corning Costar,
Tewksbury, MA) and the absorbance measured at 492 nm
using a POLARStar plate reader (BMG LABTECH,
Ortenberg, Germany).
In vivo behavior visualized by SPECT/CT
Animal studies were approved by the Finnish National
Animal Experiment Board (ESAVI/3631/04.10.03/2012) and
performed in accordance with the Animal Welfare Act (247/
1996), NIH Guide for Care and Use of Laboratory Animals
and Good Laboratory Practices for Animal Research. Fischer
albino male rats (F344/NCrHsd, Harlan, Netherlands,
236–252 g) were group-housed in a 12:12 h light/dark cycle.
The rats had free access to rodent food and tap water.
The in vivo mucoadhesive potential of the SAIB DDS after
oral administration was evaluated in rats using SPECT/CT
imaging. Six rats were quarantined the minimum of 1 week
under standard day/night lightening circles with free access
to food and water at RT. The rats received either 123I-insulin
in solution, 123I-insulin incorporated into SAIB DDS or 123I-
insulin co-administered with the SAIB DDS using oral gavage.
Depending on the yield of the labeling procedures, the rats
received 12–41 MBq of activity in a total sample volume of
1mL. 30–90min prior to dosing the radiolabeled test sys-
tems; the rats received intra-gastric sodium iodine solution
(250 mL, 10mg/mL) to saturate the thyroid with iodine
according standard to clinical practice (Notes for Guidance
on the Clinical Administration, 2019). The rats were imaged
with a four-headed small animal scanner (Mediso: NuclineVR
NanoSPECT/CT, Bioscan, Washington, DC, manufactured and
maintenance by Mediso, Budapest, Hungary) featuring
2.5mm multi-pinhole rat apertures (Scivis, G€ottingen,
Germany). Imaging was performed under isoflurane anesthe-
sia (2–3% v/v) in O2, and the body temperature was main-
tained warm using a heated animal bed (Equipement
Veterinaire Minerve, Esternay, France). Biodistribution of the
radiolabelled test systems was followed for 22 h. After the
last time point of imaging, the rats were sacrificed by cer-
vical dislocation. Whole body SPECT images were collected
in 16–20 projections using 20–30 s per projection resulting in
a total acquisition time of 18min. CT imaging was accom-
plished with 45 kVp tube voltage in 180 projections. For 3D
co-registration and analysis, the SPECT images were recon-
structed with HiSPECT NG software (Scivis, G€ottingen,
Germany) and fused with CT datasets by using the molecular
imaging suite InVivoScopeTM (Bioscan, Washington, DC).
Statistical analysis
Statistical analysis was carried out in GraphPad Prism version
5.04 (GraphPad, La Jolla, CA) using one-way analysis of
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variance (ANOVA) with an alpha value of 0.05%, followed by
Tukey’s posttest. Data are shown as mean± standard devi-
ation (S.D.). Unless otherwise stated, all tests were run in
independent triplicates.
Results and discussion
Physiologically relevant temperature and immersion
media enhance mucoadhesive behavior of SAIB
When utilizing the SAIB DDS as a potential biomaterial,
knowledge about its rheological properties is important, as
they closely relates to drug release behavior (Sz}uts et al.,
2008, 2010), spreading and adhesion on the mucosa, hence
residence time in vivo (Carlfors et al., 1998; Edsman et al.,
1998; Desai & Blanchard, 2000; Chang et al., 2002) and micro-
structural stability (Partal et al., 1997). At RT, the SAIB DDS is
highly viscous, hence with a low spreadability. However,
when increasing the temperature from 22 C to 37 C, tem-
perature sweep profiles (Figure 1) demonstrated a fivefold
decrease in the elastic modulus (G0), i.e. the hardness of SAIB
DDS decreases from 0.04 Pa ± 0.01 to 0.008 Pa ± 0.004. This
change in viscosity allows the SAIB DDS to spread on the
surface of the GIT at body temperature, thereby facilitating a
larger contact area between the SAIB DDS and
the biobarrier.
A similar temperature dependency has been demon-
strated for well-known bioadhesive biomaterials (Lin et al.,
2012; Kong et al., 2015), and sucrose ester stabilized emul-
sions (Partal et al., 1997), explained by thermal agitation facil-
itating structural breakdown of the continuous phase, in this
case being SAIB, hence decreasing the hardness of the
material (Partal et al., 1997). To investigate the stability of
SAIB DDS upon storage and at use, the rheological behavior
was evaluated both at room and physiological temperature
(22 and 37 C) (Figure 2(A,B)) subsequent to storage at vari-
ous temperatures (5, 22, and 37 C) for up to 14 days (Figure
2(A,B) and supplementary). When running rheological ana-
lysis at 22 C, SAIB DDS stored at 37 C is characterized by a
higher G0 compared to the SAIB DDS stored at lower temper-
atures (5 and 22 C, Figure 2(A)) and considerably more stress
was needed to cause a 10% decrease in G0 after storage at
37 C, when comparing the samples tested (Supplementary
data). This behavior is likely occurring due to irreversible
coalescence or reversible deflocculation of the dispersed
phase (alcohol), and eventually evaporation hereof into the
continuous phase as a consequence of the increased storage
temperature (Partal et al., 1997), confirming the data from
Figure 1. Thus, when subjecting the destabilized system to a
rapid temperature decrease from 37 to 22 C, the dispersed
phase is not reversed into its originally evenly distributed
droplets. Instead, the continuous phase is forming a more
rigid network resulting in an increased G0 (Partal et al., 1997).
Accordingly, when increasing the measuring temperature
from 22 to 37 C, no difference was observed in the fre-
quency (Figure 2(B)) as partial destabilization of the system
has already occurred. Thus, SAIB DDS system was stored at
22 C until further use.
As presence of biological fluids affects the rheological
behavior of gel-based systems (Chang et al., 2002), the rheo-
logical properties of SAIB DDS were investigated during 72 h
immersion in MES and SSIF at 37 C (Figure 2(C)).
Additionally, the amount of volatile matter (i.e. amount of
substance evaporated) in SAIB DDS was determined after up
to 48 h immersion in MES or SSIF buffer. From Figure 2(C), it
is evident that immersion in MES or SSIF buffer (both pH 6.5)
resulted in an increase of G0 as a function of time corre-
sponding to a loss of volatile matter from the SAIB DDS
already after 1 h immersion in buffer (Figure 2(D)); the same
behavior as observed after 7 days storage at 37 C (Figure
2(A)). This supports the previously stated hypothesis that irre-
versible coalescence of the ethanol phase is occurring.
Interestingly, the increase in G0 at 1 rad/s and loss of volatile
matter occurred in a delayed manner for the SAIB DDS
immersed in the SSIF compared to MES buffer. It is previ-
ously reported that addition of lipophilic co-surfactants, such
as the ones present in SSIF, can penetrate into the palisade
layer of sucrose esters, hence induce swelling of the system
(Rodriguez-Abreu et al., 2005). Such swelling allows for
increased hydration of the SAIB DDS, thus increasing the per-
centage of volatile matter. This finding is highly interesting,
as hydration of the delivery system is closely related to
mucoadhesion, as well as to the diffusion of bioactive com-
pounds through the intestinal mucosa (Peppas & Buri, 1985).
SAIB DDS is thus believed to have highly interesting proper-
ties as DDS targeting the intestinal mucus due to high
spreadability, swelling and consequently mucoadhe-
sive behavior.
SAIB displays considerable mucoadhesion to
biosimilar mucus
One approach to increase the bioavailability of orally deliv-
ered biopharmaceuticals is to prolong the residence time, i.e.
contact time of the drug with the mucosa at the relevant
absorption site, which can be done by the development of a
mucoadhesive delivery system (Ivarsson & Wahlgren, 2012). A
commonly used method to assess the degree of mucoadhe-
sion is to evaluate the potential changes in viscosity caused
by the interaction between 1 and 3% (w/v) mucin dispersed
in the biorelevant buffer and the delivery system of interest,
Figure 1. Temperature sweep. Data are plotted as triplicate samples of SAIB
DDS (w/w) as a function of temperature.
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using equation (1) (Hassan & Gallo, 1990; Oechsner & Keipert,
1999; Kesavan et al., 2010; H€agerstr€om et al., 2012; Ivarsson
& Wahlgren, 2012):
gadhesion ¼ gtotal system– gmucin reference– gdelivery system (1)
It has been shown, however, that a homogenized porcine
mucus gel (2% w/w) serves as a better model compared to a
mucin dispersion (Madsen et al., 1996a, 1996b). Yet, mucoad-
hesion cannot solely be ascribed to the formation of second-
ary bonds, such as the interaction between the hydrophobic
backbone of the SAIB and the glycoprotein chains on the
mucin. Mucus as a whole behaves like a steric and inter-
active barrier to diffusion of drugs (Madsen et al., 1996a,
1996b; Lai et al., 2009; Leileg & Ribbeck, 2011), for which rea-
son we chose to implement a recently developed biosimilar
mucus mixture containing 5% (w/v) mucin (Boegh et al.,
2014, 2015) in the characterization of the mucoadhesion of
the DDS (Figure 3). When comparing the biosimilar mucus
with porcine intestinal mucus, a similar microstructure, as
well as rheological properties, is observed (Boegh et al.,
2014, 2015).
As mucoadhesion is affected by the SAIB concentration
(Madsen et al., 1996a, 1996b), mixing ratios of 2:1, 1:1, and
1:2 (biosimilar mucus:SAIB, v/v) were used for the evaluation.
When calculating gadhesion at a shear rate of both 9 and
14 s–1 (both values well within the linear region of the viscos-
ity profile) an increase in viscosity was observed for the ratio
1:1 (biosimilar mucus:SAIB, v/v) suggesting an interaction
between the SAIB DDS and the biosimilar mucus. The inter-
action observed is likely primarily due to the formation of a
high number of weak secondary bonds formed between the
hydrophobic backbone of the SAIB and the mucin strands.
Negative gadhesion values were, however, obtained for the
ratios 2:1 and 1:2. In those mixtures, the dominant phase
was either SAIB or biosimilar mucus, and thus the network
Figure 2. Effect of storage and incubation on the rheological profile of the SAIB DDS (A) and (B) frequency sweep of SAIB DDS stored at different temperatures
and measured at either 22 C (A) or 37 C (B). (C) G0 after immersion of SAIB DDS in either 10mM MES buffer or simulated small intestinal fluid (SSIF), both pH 6.5
and measured at 37 C, and (D) loss on drying after exposure to the same buffer and temperature conditions as described for (C). Data are plotted as
mean ± S.D.; n¼ 3.
Figure 3. Continuous ramp flow with increasing shear rates from 0 to 25 s–1.
Data are plotted as a representative sample chosen from triplicate
measurements.
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characterized being only the dominant phase, suggesting
gtotal system¼ gdelivery system for those mixtures, explaining the
negative gadhesion.
For the mixing ratio of 2:1, biosimilar mucus being the
dominant phase, the number of secondary bonds between
biosimilar mucus and SAIB is lower when compared to the
mixing ratio of 1:1, thus the mixtures resistance to deform-
ation is not increased. This suggests that a local minimum
concentration of the SAIB DDS is required to form significant
interactions with the biosimilar mucus. At a ratio of 1:2, the
network of the dominant phase (SAIB) is disrupted and
smaller flow units are formed, thus decreasing the total vis-
cosity of the mixture (Sz}uts et al., 2010). On the contrary,
when equivalent volumes are present, no phase is dominat-
ing, and interactions are built, resulting in a positive gadhesion.
Such eutectic behavior is known from, e.g. binary blends of
fatty acids (Costa et al., 2009), where complete miscibility is
only observed for equimolar ratios of fatty acids. What
remains unanswered from this approach is, which ratio
between biosimilar mucus and the delivery system best rep-
resents the actual in vivo situation. It is, however, shown that
the interaction between SAIB DDS and the biosimilar mucus
is possible given the optimal dosing volume.
SAIB DDS remains stable and retains insulin within its
matrix when subjected to gastric processing
For an oral formulation, the stomach represents one of the
first barriers the formulation must overcome for successful
delivery. Therefore, the effects of physical shear stress in the
antrum to the SAIB DDS was evaluated using the dynamic
gastric model (Figure 4(A)). The dynamic gastric model is
designed to simulate several unique and often disregarded
features of the stomach, such as feedback regulated addition
of acid and the physical shear forces of the antral compart-
ment (Vardakou et al., 2011). Hence, the model is highly rele-
vant for the evaluation of pharmaceutical oral dosage forms
as it allows dosage form integrity, drug release and food
effects to be studied in vitro (Wickham et al., 2012). Here, we
examined insulin-loaded SAIB DDS (w/w) in the dynamic
gastric model experiments simulating fasted state conditions.
As shown in Figure 4(A), the observed concentration of insu-
lin in solution gradually increased from 10min to 40min.
After 40min, the total insulin in solution corresponded to
20% of the theoretical content, e.g. 20% insulin released
from the SAIB DDS in the stomach. Despite the release, the
microstructure of the SAIB DDS remained intact (images,
Figure 4(A)), suggesting that the SAIB DDS is capable of pro-
tecting insulin in the stomach and delivering the majority of
insulin to the small intestine.
Furthermore, insulin release from SAIB DDS was evaluated
in MES and the biologically relevant SSIF buffer, both pH 6.5
(Figure 4(B)). In MES buffer, an accumulated release of
52.9%±15 was observed, corresponding to 88.1 mg/mL ± 25.
However, when submerging SAIB DDS into SSIF buffer, the
accumulated release was only 1.5%±1, corresponding to
2.5 mg/mL ± 2. The significant difference in release when
comparing the two buffers is caused by the observed swel-
ling of the SAIB DDS matrix as a result of the lipophilic co-
surfactants in SSIF buffer, as previously discussed. An
increase in the hydrodynamic diameter of SAIB-based nano-
particles is previously shown to prevent diffusion through a
poly-lactic acid membrane surrounding the SAIB based nano-
particles (Jølck et al., 2014). Thus, it can be speculated that
the increased hydrodynamic diameter caused by swelling in
the present study also explains the very limited insulin
release observed in Figure 4(B). Moreover, the co-surfactants
in the SSIF buffer might adhere to the surface of the SAIB
DDS, thus preventing diffusion of insulin from the SAIB DDS
matrix to the buffer.
The SAIB gel system does not impair epithelial integrity
and cell viability
Prior to conducting in vivo studies, the effect of SAIB DDS on
the epithelial integrity and cell viability was evaluated using
Caco-2 cell monolayers (Brøndsted et al., 1995) resembling
intestinal epithelium. No effect was observed on the transe-
pithelial electrical resistance (TEER) values across the mono-
layer exposed to the SAIB gel (108%±1 (S.D.) relative to
Figure 4. (A) Insulin release from SAIB DDS during the dynamic gastric model experiment simulating fasted state in vivo conditions. The image is obtained using
light microscopy with a magnification of 20. (B) Release of insulin at 37 C from SAIB DDS after immersion in either 10mM MES buffer or simulated small intestine
fluid (SSIF), both pH 6.5. Data are plotted as mean ± S.D.; n¼ 3. The images are obtained using light microscopy with a magnification of 100.
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control), proving that tightness hence integrity of the cell
monolayer was intact. Furthermore, the results showed that
addition of 50 mL SAIB DDS to the apical side of Caco-2 cell
monolayers did not impair cell viability (104%±3 (S.D.) rela-
tive to control) (Figure 5(B)). Altogether, there was no indica-
tion that SAIB compromises the integrity of the epithelium.
This finding is in agreement with reported long-term in vivo
studies in rats, dogs, monkeys, and humans, showing no
signs of toxic effect post oral administration of SAIB
(Reynolds, 1998; Reynolds & Chappel, 1998; Food Additive
Status List, 2002). In addition, it was revealed that the etha-
nol concentration used in the SAIB DDS did not have any
effect on epithelial integrity and cell viability. Thus, it can be
concluded that the tested SAIB DDS were compatible with
the cell monolayers. The permeated amount of 3H-mannitol,
included as a hydrophilic paracellular permeability marker,
Figure 5. (A) Permeation of 3H-mannitol across a Caco-2 cell monolayer and permeation of 3H-mannitol when incorporated into SAIB DDS. (B) Cell viability (black
bar) and epithelial integrity (open bar), assessed by transepithelial electrical resistance (TEER) of Caco-2 cell monolayers after application of SAIB DDS with either
3H-mannitol incorporated into SAIB DDS or co-administered with SAIB DDS for 4 h. Data are plotted as mean ± S.D.; n¼ 3.
Figure 6. Representative SPECT/CT images showing the biodistribution of orally administered 123I-insulin 10min, 2 h and 22 h after administration. The scale bar
is the same for all images.
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was not increased, but on the other hand considerably
decreased when incorporated into the SAIB DDS
(Figure 5(A)).
SAIB DDS considerably increases intestinal residence
time in vivo
The mucoadhesive behavior of orally administered SAIB DDS
was evaluated in male F344/NCrHsd rats. Insulin, in the form
of 123I-insulin was used as a model cargo for two purposes.
First, the localization of the SAIB DDS encapsulating the mol-
ecule in the intestine, hence the mucoadhesive behavior
could be assessed by SPECT/CT imaging. Second, the find-
ings from the studies in the dynamic gastric model, suggest-
ing that the SAIB DDS is capable of delivering the vast
majority of the insulin to the small intestine target site could
be verified.
From Figure 6, it can be concluded, that the SAIB DDS
clearly retained the radiolabel, likely still attached to the
insulin, in the intestines for up to 22 h (Figure 6(C)). Contrary,
orally administered 123I-insulin in ultrapure water alone did
not show the presence of 123I-label in the intestines, whereas
a 123I signal was primarily detected in the stomach. Two
hours post administration, a fraction of the 123I-label was
observed in the bladder, suggesting excretion of the 123I-
label via the urine. Presence of 123I-activity in the animal
cages after 22 h further supports this observation. It should
of course be kept in mind that the radiolabel might be
detached from the insulin during the experiment. Speaking
against this is, though, that the distribution area of the radio-
label was much more confined for the 123I-insulin-loaded
SAIB DDS as compared to the controls (123I-insulin alone and
123I-insulin co-administered with SAIB DDS), indicating that
123I-insulin remained encapsulated inside the SAIB DDS
matrix. These findings are supported by the fact that only
1.5% insulin release was observed in SSIF and a similar ten-
dency is expected in vivo. Moreover, a previous study
showed the presence of SAIB in the intestine 24 h after oral
administration (Phillips et al., 1976), supporting the conclu-
sion that 123I is still entrapped in the SAIB DDS.
Conclusions
In conclusion, we believe that SAIB is a very interesting bio-
material that can be applied to obtain mucoadhesion leading
to increased intestinal retention in vivo as hypothesized. We
base this conclusion on the combination of findings from
thorough rheological assessment showing distinct mucoad-
hesion between the SAIB DDS and biosimilar mucus, and
from in vivo studies revealing an increased intestinal resi-
dence time from 2h to 22 h when comparing 123I-insulin in
solution with 123I-insulin loaded in SAIB DDS. Moreover, both
the dynamic gastric model and in vivo studies suggest, that
SAIB DDS is capable of protecting its cargo against elimin-
ation after oral dosing in the stomach.
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